Literature DB >> 23517662

Screening for substance use disorders in first-episode psychosis: implications for readmission.

Albert Batalla1, Clemente Garcia-Rizo, Pere Castellví, Emili Fernandez-Egea, Murat Yücel, Eduard Parellada, Brian Kirkpatrick, Rocío Martin-Santos, Miguel Bernardo.   

Abstract

INTRODUCTION: Screening of substance use may prove useful to prevent readmission after the first episode of psychosis. The aim of the present study was to evaluate the influence of drug use on readmission risk in a first-episode psychosis sample, and to determine whether the cannabis/cocaine subscale of the Dartmouth Assessment of Lifestyle Inventory (DALI) is a better predictive instrument than urinary analysis.
METHODS: After admission, first-episode psychotic patients were interviewed for substance use and assessed with the DALI scale. They also underwent blood and urine sampling. Time to readmission was studied as a dependent outcome. The Kaplan-Meier estimator was applied to estimate the survival curves for bivariate analysis. The Cox proportional hazards model for multivariate analysis was assessed in order to control for potential confounders. ROC curve and validity parameters were used to assess validity to detect readmission.
RESULTS: Fifty-eight patients were included. The DALI cannabis/cocaine subscale and urinalysis were associated with increased readmission risk in survival curves, mainly the first five years of follow-up. After controlling for potential confounding variables for readmission, only the DALI cannabis/cocaine subscale remained as a significant risk factor. In terms of validity, the DALI cannabis/cocaine subscale was more sensitive than urinalysis. Alcohol assessments were not related to readmission.
CONCLUSIONS: The findings demonstrated that a quick screening self-report scale for cannabis/cocaine use disorders is superior to urinary analysis for predicting readmission. Future research should consider longitudinal assessments of brief validated screening tests in order to evaluate their benefits in preventing early readmission in first-episode psychosis.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23517662      PMCID: PMC4390132          DOI: 10.1016/j.schres.2013.02.031

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  46 in total

1.  Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia.

Authors:  M P Salyers; K T Mueser
Journal:  Schizophr Res       Date:  2001-03-01       Impact factor: 4.939

Review 2.  Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden.

Authors:  E Cantor-Graae; L G Nordström; T F McNeil
Journal:  Schizophr Res       Date:  2001-03-01       Impact factor: 4.939

3.  Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study.

Authors:  Olalla Caseiro; Rocío Pérez-Iglesias; Ignacio Mata; Obdulia Martínez-Garcia; Jose Maria Pelayo-Terán; Rafael Tabares-Seisdedos; Victor Ortiz-García de la Foz; José L Vázquez-Barquero; Benedicto Crespo-Facorro
Journal:  J Psychiatr Res       Date:  2012-06-19       Impact factor: 4.791

4.  Lifetime history of substance misuse in first-episode psychosis: prevalence and its influence on psychopathology and onset of psychotic symptoms.

Authors:  Moayyad Kamali; Orfhlaith McTigue; Peter Whitty; Maurice Gervin; Mary Clarke; Stephen Browne; Conall Larkin; Eadbhard O'Callaghan
Journal:  Early Interv Psychiatry       Date:  2009-08       Impact factor: 2.732

Review 5.  Substance use disorder among people with first-episode psychosis: a systematic review of course and treatment.

Authors:  Jennifer P Wisdom; Jennifer I Manuel; Robert E Drake
Journal:  Psychiatr Serv       Date:  2011-09       Impact factor: 3.084

6.  Dartmouth Assessment of Lifestyle Instrument (DALI): a substance use disorder screen for people with severe mental illness.

Authors:  S D Rosenberg; R E Drake; G L Wolford; K T Mueser; T E Oxman; R M Vidaver; K L Carrieri; R Luckoor
Journal:  Am J Psychiatry       Date:  1998-02       Impact factor: 18.112

Review 7.  Substance misuse in patients with schizophrenia: epidemiology and management.

Authors:  David J Kavanagh; John McGrath; John B Saunders; Glenys Dore; Dianne Clark
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 8.  Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies.

Authors:  M Alvarez-Jimenez; A Priede; S E Hetrick; S Bendall; E Killackey; A G Parker; P D McGorry; J F Gleeson
Journal:  Schizophr Res       Date:  2012-06-01       Impact factor: 4.939

9.  Cannabis abuse and the course of recent-onset schizophrenic disorders.

Authors:  D H Linszen; P M Dingemans; M E Lenior
Journal:  Arch Gen Psychiatry       Date:  1994-04

10.  Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia.

Authors:  V Peralta; M J Cuesta
Journal:  Psychiatry Res       Date:  1994-07       Impact factor: 3.222

View more
  3 in total

Review 1.  Assessing marijuana use in bariatric surgery candidates: should it be a contraindication?

Authors:  Christina M Rummell; Leslie J Heinberg
Journal:  Obes Surg       Date:  2014-10       Impact factor: 4.129

2.  Psychiatric Rehospitalization: Development of a Person-Level Indicator for Care Planning and Quality Assurance.

Authors:  Christopher M Perlman; John P Hirdes; Simone Vigod
Journal:  Prim Care Companion CNS Disord       Date:  2015-07-23

3.  Continued cannabis use at one year follow up is associated with elevated mood and lower global functioning in bipolar I disorder.

Authors:  Levi Roestad Kvitland; Ingrid Melle; Sofie Ragnhild Aminoff; Christine Demmo; Trine Vik Lagerberg; Ole Andreas Andreassen; Petter Andreas Ringen
Journal:  BMC Psychiatry       Date:  2015-02-05       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.